ROKIT America sells NMN-based dietary supplements and is developing an AI-powered organ regeneration platform for the Americas. The company's primary revenue driver is its Reverse Aging Product line, a suite of seven supplements centered on NMN, an NAD+ precursor marketed for longevity. ROKIT America sells these supplements through e-commerce and wholesale distributors in the U.S., Korea, and Vietnam. The company's emerging business is the Organ Regeneration Platform, licensed from its parent company, ROKIT Healthcare. This system treats chronic wounds, such as diabetic foot ulcers, by using a clinical 3D bioprinter and an AI wound-scanning app to create customized patches from a patient’s own fat tissue. The company employs a "razor and blades" business model for this platform, generating recurring revenue from the sale of single-use kits to hospitals and distributors. ROKIT America intends to expand this technology into cartilage and kidney regeneration. The company functions as a commercialization subsidiary for ROKIT Healthcare, which provides all technology, manufacturing, and management services. ROKIT America currently has no employees of its own and relies on a shared services agreement with its parent for all operational functions. Strategy focuses on scaling digital marketing for supplements and establishing a sales and distribution infrastructure for the medical platform across the Americas.